A 52-week follow-up, multi-center, randomized, double-blinded comparison of efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in Chinese population.
Abstract
[INTRODUCTION] To investigate the efficacy and safety of Cutegel MAX (Cutegel) in the correction of moderate-to-severe nasolabial folds (NLFS) compared to Restylane (Restylane, control).
[METHODS] This study was a 52-week, multicenter, randomized, double-blinded, active-controlled clinical trial. Qualified participants with moderate-to-severe NLFs were randomly assigned in a 1:1 ratio to receive Cutegel or Restylane. For the primary efficacy endpoint, the response rate was defined as the percentage of subjects exhibiting an improvement of at least one-point based on blinded evaluation of Wrinkle Severity Rating Scale (WSRS) at 24 weeks after injection. Other secondary efficacy endpoints and treatment-emergent adverse events (TEAEs) were assessed.
[RESULTS] Of 340 subjects randomized, 317 completed the week 52 visit. In the per protocol set (PPS), the blinded evaluator-assessed response rates at week 24 were 81.17% for Cutegel versus 77.56% for Restylane ( = 0.327). The between-group treatment differences in response rates were 3.60% [95% confidence interval (CI) = (-5.39%, 12.60%)], which demonstrated the noninferiority of Cutegel. Other secondary efficacy endpoints supported this. No significant differences were observed in the occurrence of adverse events between the two groups.
[CONCLUSION] Similar to Restylane, Cutegel was effective and well tolerated in correcting moderate-to-severe NLFs among the Chinese population.
[METHODS] This study was a 52-week, multicenter, randomized, double-blinded, active-controlled clinical trial. Qualified participants with moderate-to-severe NLFs were randomly assigned in a 1:1 ratio to receive Cutegel or Restylane. For the primary efficacy endpoint, the response rate was defined as the percentage of subjects exhibiting an improvement of at least one-point based on blinded evaluation of Wrinkle Severity Rating Scale (WSRS) at 24 weeks after injection. Other secondary efficacy endpoints and treatment-emergent adverse events (TEAEs) were assessed.
[RESULTS] Of 340 subjects randomized, 317 completed the week 52 visit. In the per protocol set (PPS), the blinded evaluator-assessed response rates at week 24 were 81.17% for Cutegel versus 77.56% for Restylane ( = 0.327). The between-group treatment differences in response rates were 3.60% [95% confidence interval (CI) = (-5.39%, 12.60%)], which demonstrated the noninferiority of Cutegel. Other secondary efficacy endpoints supported this. No significant differences were observed in the occurrence of adverse events between the two groups.
[CONCLUSION] Similar to Restylane, Cutegel was effective and well tolerated in correcting moderate-to-severe NLFs among the Chinese population.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 합병증 | nasolabial folds
|
scispacy | 1 | ||
| 재료 | hyaluronic acid
|
히알루론산 | dict | 1 | |
| 약물 | Restylane
|
C1101698
Restylane
|
scispacy | 1 | |
| 약물 | [INTRODUCTION] To
|
scispacy | 1 | ||
| 질환 | NLFs
→ nasolabial folds
|
scispacy | 1 | ||
| 질환 | WSRS
→ Wrinkle Severity Rating Scale
|
scispacy | 1 | ||
| 질환 | Restylane
|
scispacy | 1 |
MeSH Terms
Adult; Female; Humans; Male; Middle Aged; China; Cosmetic Techniques; Dermal Fillers; Double-Blind Method; East Asian People; Follow-Up Studies; Hyaluronic Acid; Nasolabial Fold; Skin Aging; Treatment Outcome
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Choroidal ischemia after self-injection of hyaluronic acid filler.
- Intra-articular therapies for synovial joint dysfunction: a comprehensive integrative review.
- Clinical safety of a low-modification hyaluronic acid filler (MoD 2%) for facial rejuvenation.
- A Fibrous-Porous Microsphere-Based Composite Filler for Synchronized Immediate and Long-Term Soft Tissue Restoration.